|Bid||144.60 x 1000|
|Ask||199.50 x 800|
|Day's Range||183.91 - 189.98|
|52 Week Range||105.69 - 203.91|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||37.40|
|Earnings Date||Feb 02, 2021|
|Forward Dividend & Yield||1.60 (0.87%)|
|Ex-Dividend Date||Nov 23, 2020|
|1y Target Est||221.33|
WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Cantel Medical Corp. (“Cantel”) (NYSE: CMD) regarding possible breaches of fiduciary duties and other violations of law related to Cantel’s agreement to be acquired by STERIS plc (“STERIS”) (NYSE: STE). Under the terms of the agreement, Cantel’s shareholders will receive approximately $16.93 in cash and 0.33787 of a share of STERIS per share. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cantel-medical-corp.You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or firstname.lastname@example.org.Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.Attorney advertising. Prior results do not guarantee a similar outcome.CONTACT: Rigrodsky Law, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (Toll Free) (302) 295-5310 Fax: (302) 654-7530 email@example.com https://rl-legal.com
STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cantel Medical Corp. ("CMD" or the "Company") (NYSE: CMD) in connection with the proposed acquisition of the Company by STERIS plc ("STERIS") (NYSE: STE). Under the terms of the merger agreement, STERIS will acquire CMD in a mixed cash-and-stock transaction, pursuant to which CMD shareholders will receive $16.93 in cash and 0.33787 of a STERIS ordinary share for each CMD share that they own, representing implied per-share merger consideration of approximately $84.66 based upon STERIS' January 11, 2021 closing price of $200.46.